Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study

View Full Paper
Ask AI
Bookmark
Share

Authors

BNBehnam Noorani

Discussion

Loading...

Member takes

Overview

Phase 3 trial demonstrates improved efficacy and safety of 48 mg epcoritamab compared to lower doses in R/R FL, indicating potential for effective management.

Key Points

  • Epcoritamab's 48 mg dosing regimen significantly enhances progression-free survival in patients with R/R FL, ensuring better outcomes.
  • In a Phase 3 trial, the 48 mg dosage exhibited improved efficacy and safety metrics compared to lower dosages in treating R/R FL.
  • Population PK analyses supported the safety profile of epcoritamab, showing no increase in adverse events across varying doses.
  • Utilizing a modified 3-step SUD regimen and adjunct treatments like dexamethasone effectively mitigates cytokine release syndrome risk.

Cite This Study

Behnam Noorani (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d451https://doi.org/10.1182/blood-2025-1820
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025
  3. 3Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025
  4. 4Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  5. 5Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial2025